 |
Dojindo
Newsletter Vol.2
Review
Oxidative
Stress, DNA Damage and Human Diseases
Table
of Contents
Oxidative
Stress, DNA Damage and Human Diseases
Spectrum of DNA damage resulting from oxidative
stress
Enzymatic repair of oxidative DNA damage
Oxidative stress and human diseases
Detection and quantification of oxidative DNA
damage by the ARP assay
References
Product Information
Yoke
W. Kow, Ph.D.
Division of Cancer Biology, Department of Radiation Oncology,
Emory University School of Medicine, 145 Edgewood
Avenue, Atlanta, GA 30335
Reactive
oxygen species (ROS), such as hydrogen peroxide, superoxide
and hydroxyl radical are products of oxygen metabolism in
all aerobic organisms. ROS are generated as a result of energy
production from mitochondria (from the electron transport
chain), as part of an antimicrobial (1)
or antiviral (2) response, as well as
detoxification reactions carried out by the cytochrome P-450
system (3, 4). Environmental
agents such as ultraviolet light, ionizing radiation, redox
chemicals and cigarette smoke also readily generate ROS. The
antioxidant defense system in most cells is composed of two
components, the antioxidant enzymes component which includes
enzymes such as superoxide dismutase, catalase and glutathione
peroxidase, and the low molecular weight antioxidants component
that includes vitamins A and E, ascorbate, glutathione and
thioredoxin. These substances are the body's natural defense
against endogenous generated ROS and other free radicals,
as well as ROS generated by external environmental factors.
Oxidative stress occurs when the production of ROS exceeds
the body's natural antioxidant defense mechanisms, causing
damage to biomolecules such as lipids, proteins and DNA.
Spectrum
of DNA damage resulting from oxidative stress
Oxidative
damage to DNA is a result of interaction of DNA with reactive
oxygen species (ROS), in particular the hydroxyl radical.
Superoxide and hydrogen peroxide are normally not reactive
towards DNA. However, in the presence of ferrous or cuprous
ion (the Fenton reaction), both superoxide and hydrogen peroxide
are converted to the highly reactive hydroxyl radical. Hydroxyl
radical produces a multiplicity of modifications in DNA. Oxidative
attack by OH radical on the deoxyribose moiety will lead to
the release of free bases from DNA, generating strand breaks
with various sugar modifications and simple abasic (AP) sites.
In fact, one of the major types of damage generated by ROS
is AP site, a site where a DNA base is lost.
AP
sites are also formed at an appreciable rate from spontaneous
depurination. It is estimated that at least 10,000 depurination
events occur per cell per day under physiological conditions.
A similar amount of AP site is thought to be generated by
normal aerobic respiration. In addition to AP site, a wide
spectrum of oxidative base modification occurs with ROS (Figure
1). The C4-C5 double bond of pyrimidine
is particularly sensitive to attack by OH radical, generating
a spectrum of oxidative pyrimidine damage including thymine
glycol, uracil glycol, urea residue, 5-OHdU, 5-OHdC, hydantoin
and others. Similarly, interaction of OH radical with purines
will generate 8-OHdG, 8-OHdA, formamidopyrimidines and other
less characterized purine oxidative products. It has been
estimated that endogenous ROS can result in about 200,000
base lesions per cell per day. The biological consequences
of many of the oxidative products are known. For example,
unrepaired thymine glycol is a block to DNA replication and
is thus potentially lethal to cells. On the contrary, 8-oxoG,
an abundant oxidative damage to dG, is readily bypassed by
the DNA polymerase and is highly mutagenic. Unrepaired 8-oxoG
will mispair with dA, leading to an increase in G to T transition
mutations.

Figure 1. Chemical structure of some of the stable
oxidative DNA base lesion.
|
Enzymatic
repair of oxidative DNA damage
In
order to maintain the fidelity of genetic material, all organ
isms have evolved many different repair pathways to remove
various types of DNA damage, resulting from either endogenous
or external DNA reactive agents. Oxidative damage is repaired
by a ubiquitous base excision repair pathway (5,
6). Base damage is recognized by DNA N-glycosylase.
There are two major N-glycosylases for oxidative base damage
(a deamination product such as uracil is recognized by uracil
N-glycosylase). Endonuclease III from E. coli is the prototype
repair enzyme that recognizes many types of oxidative pyrimidine
damage (7, 8). Homologues
of endonuclease III are found in all cells examined, and its
gene has been cloned from bacteria, yeast, mouse, and human
cells. The substrate specificity of various endonuclease III
homologues appear to be similar (9, 10).
The enzyme has an associated b-lyase activity. After the release
of the damaged base by endonuclease III, the enzyme cleaves
to the phosphodiester bond 3' to the AP site, leaving behind
a 3'modified sugar moiety, 4-hydroxypentenal (11).
On the other hand, oxidative purine damage is recognized by
formamidopyrimidine N-glycosylase (fpg; (12,
13)). Functional homologues of the bacterial
fpg protein are present in yeast and human cells. The eukaryotic
enzyme that recognizes 8-oxoG is called 8-xooG glycosylase
(OGG1 gene product) and shares no amino acid sequence homology
with the bacterial fpg protein (14).
The substrate specificity of bacterial fpg and eukaryotic
OGG1 protein is similar, recognizing 8-oxoG and formamidopyrimidines.
However, the bacterial fpg protein has an associated b,d-lyase
activity, leaving behind a 3' phosphate terminus (15, 16).
The eukaryotic OGG1 protein is a b-lyase, leaving behind a
3' 4-hydroxypentenal residue. The 3' residue (either the 4-hydroxypentenal
or phosphoryl group) left behind by these N-glycosylases are
further processed by AP endonucleases, generating the 3' OH
that is required for repair synthesis catalyzed by DNA polymerase.
There are two major types of AP endonuclease, endonuclease
III and the exonuclease IV. In E. coli, both AP endonucleases
are present, with exonuclease III being the major AP endonuclease.
In human cells, the major AP endonuclease is exonuclease III
and in yeast, the major activity is endonuclease IV. After
the 3' end of the DNA is processed by AP endonucleases, the
repair process is completed following repair synthesis and
ligation by DNA polymerase and ligase, respectively.
Oxidative stress and human diseasesOxidative
stress has been thought to contribute to the general decline
in cellular functions that are associated with many human
diseases including Alzheimer disease (17,
18), amyotrophic lateral sclerosis (ALS;
(19, 20)), Parkinson
disease (21, 22),
atherosclerosis (23, 24),
ischemia/reperfusion neuronal injuries, degenerative disease
of the human temporomandibular-joint (25),
cataract formation (26,
27), macular degeneration (20, 28),
degenerative retinal damage (29), rheumatoid
arthritis (30), multiple sclerosis (31),
muscular dystrophy (32, 33),
human cancers (34, 35)
as well as the aging (36, 37)
process itself. Increased cellular level of ROS due to oxidative
stress can result in an increased steady state level of oxidative
DNA damage. There is increasing evidence that an increased
level of oxidative damage such as AP site is detected in cells
obtained from ALS and Alzheimer patients or after ischemia/reperfusion.
Due to the fact that many human diseases might be resulting
from chronic oxidative stress and the magnitude of oxygen
damage to DNA that is associated with oxidative stress, it
this important to have a simple and accurate procedure for
estimating the level of oxidative DNA damage in oxidative
stressed cells.
Detection and quantification of oxidative
DNA damage by the ARP assay
ARP
reagent (N'-aminooxymethyl-carbonylhydrazino-D-biotin, Figure
2) is a biotinylated hydroxylamine derivative. The chemical
reacts specifically with an aldehyde group, thus allowing
the detection of DNA modifications that resulted in the formation
of an aldehyde group. AP site in DNA exists in equilibrium
between the ring closed and the ring opened form (Figure
3). Approximately 5% of the AP site is in the ring opened
form, which has an active aldehyde group. ARP, a biotinylated
alkoxyamine
Figure
2. Chemical structure of ARP reagent
|
Figure
3. Chemical structure of an AP site
|
(Figure
2) reacts specifically with the aldehyde group in the
ring opened AP site. After treating DNA containing AP sites
with ARPreagent, AP sites are thus tagged with a biotin residue.
By using an excess amount of ARP reagent, essentially all
AP sites can be converted to biotin-tagged AP sites. The amount
of biotinylated AP sites can then be easily quantified with
an ELISA-like assay, using avidin-biotin complex conjugated
with either horseradish peroxidase or alkali phosphatase as
an indicator enzyme (Figure 4). This procedure
has been successfully used by laboratories for accurate measurement
of AP sites in DNA (38, 39, 40, 41). A modification of the
ELISA-like ARP assay was made by (38),
allowing even more sensitivity in the detection of AP site.
Instead of binding DNA to a microtiter plate, DNA was bound
to a nitrocellulose membrane using a dot blot apparatus. A
microtiter plate-based AP site assay kit is currently available
from Dojindo Molecular Technologies, Inc.>

Figure 4. Principle of ARP assay
|
Many
kind of base damage are recognized by damage specific DNA
glycosylases. The substrate spectrum of DNA glycosylases varies
depending on the enzymes; some have very narrow substrate
specificity, such as uracil DNA N-glycosylase and T4 endonuclease
V, whilesome can recognize a variety of base modifications
such as endonuclease III, 8-oxoguanine N-glycosylase and alkA
protein. These glycosylases remove modified bases, leaving
behind either intact AP sites or modified sugar moieties (4-hydroxy-pentenal)
still attached to the 3' termini of nicked DNA. Both products
of N-glycosylases still retain the active aldehyde that can
easily be quantified by the use of ARP assay. Therefore, treating
damaged DNA with a specific repair enzyme will permit the
determination of a class of base damages that is normally
recognized by the repair enzyme. The advantage of the enzyme-coupled
ARP assay is that it allows the investigator to assess the
contribution of a whole spectrum of base damage that is normally
recognized by the repair enzymes. Furthermore, if one would
like to assess the amount of oxidative DNA damage due to increased
oxidative stress, treatment of the damaged DNA with both endonuclease
III and yeast OGG1 will provide a relatively good assessment
of the total amount of oxidative base damage that has occurred
on the DNA. Endonuclease III has been shown to recognize many
different types of pyrimidine oxidative damages. Therefore
DNA samples treated with excess endonuclease III will leave
behind a 3' modified sugar moiety (4-hydroxypentenal) that
can be tagged with the ARP reagent. The amount of ARP tag
can then be determined and be used as a measurement for endonuclease
III sensitive site or an oxidative pyrimidine lesion. In fact,
the enzyme coupled-ARP assay has been used for the quantification
of thymine glycols and alkylation damage in DNA (39,
41). Similarly, oxidative purine damage
can be detected using either the yeast 8-oxoguanine glycosylase
(yOGG1) or the human 8-oxoguanine glycosylase (hOGG1). In
the latter case, the bacterial fpg protein cannot be used
since the enzyme generates a phosphoryl group. OGG1 has been
shown to recognize mostly 8-oxoG and formamidopyrimidines
(OGG does not recognize 8-oxoA), but the amount of damage
determined by the use of OGG might underestimate the total
oxidative purine damage. However, it should provide a good
assessment of the level of biologically important purine damage
present in the cells. A kit for estimating the amount of oxidative
pyrimidine and purine damage is currently under development
by Dojindo Molecular Technologies, Inc., and should be available
soon
References
-
Weiss, S. J., and LoBuglio, A. F., Laboratory Investigation,
47, 5-18 (1982).
- Griot,
C., Burge, T., Vandevelde, M., and Peterhans, E., Acta
Neuropathol., 78, 396-403 (1989).
- Scholz,
W., Schutze, K., Kunz, W., and Schwarz, M., Cancer
Res., 50, 7015-22 (1990).
- Cederbaum,
A. I., Free Radical Biology & Medicine, 7,
559-67 (1989).
-
Kow, Y. W., Faundez, G., Melamede, R. J., and Wallace,
S. S., Radiation Res., 126, 357-66 (1991).
- Kow,
Y. W., Annals of the New York Academy of Sciences,
726, 178-80 (1994).
- Kow,
Y. W., and Wallace, S. S., Biochemistry, 26,
8200-6 (1987).
- Purmal,
A. A., Rabow, L. E., Lampman, G. W., Cunningham, R. P.,
and Kow, Y. W., Mutation Res., 364, 193-207
(1996).
- Aspinwall,
R., Rothwell, D. G., Roldan-Arjona, T., Anselmino, C.,
Ward, C. J., Cheadle, J. P., Sampson, J. R., Lindahl,
T., Harris, P. C., and Hickson, I. D., Proc. Natl.
Acad. Sci. USA, 94, 109-14 (1997).
- Ikeda,
S., Biswas, T., Roy, R., Izumi, T., Boldogh, I., Kurosky,
A., Sarker, A. H., Seki, S., and Mitra, S., J. Biol.
Chem., 273, 21585-93 (1998).
- Mazumder,
A., Gerlt, J. A., Absalon, M. J., Stubbe, J., Cunningham,
R. P., Withka, J., and Bolton, P. H., Biochemistry,
30, 1119-26 (1991).
- Chetsanga,
C. J., Lozon, M., Makaroff, C., and Savage, L., Biochemistry,
20, 5201-7 (1981).
- Tchou,
J., Bodepudi, V., Shibutani, S., Antoshechkin, I., Miller,
J., Grollman, A. P., and Johnson, F., J. Biol. Chem.,
269, 15318-24 (1994).
- Radicella,
J. P., Dherin, C., Desmaze, C., Fox, M. S., and Boiteux,
S., Proc. Natl. Acad. Sci. USA, 94, 8010-5
(1997).
- Tchou,
J., and Grollman, A. P., J. Biol. Chem., 270,
11671-7 (1995).
- Rabow,
L. E., and Kow, Y. W., Biochemistry, 36,
5084-96 (1997).
- Multhaup,
G., Ruppert, T., Schlicksupp, A., Hesse, L., Beher, D.,
Masters, C. L., and Beyreuther, K., Biochem. Pharm.,
54, 533-9 (1997).
- Bozner,
P., Grishko, V., LeDoux, S. P., Wilson, G. L., Chyan,
Y. C., and Pappolla, M. A., J. Neuropathol. Experimental
Neurol., 56, 1356-62 (1997).
- Jackson,
C. E., and Bryan, W. W., Seminars in Neurology,
18, 27-39 (1998).
- Christen,
W. G., Glynn, R. J., and Hennekens, C. H., Ann. Epidemiol.,
6, 60-6 (1996).
- Radunovic,
A., Porto, W. G., Zeman, S., and Leigh, P. N., Neurosci.
Lett., 239, 105-8 (1997).
- Mukherjee,
S. K., and Adams, J. D., Jr., Molecular & Chemical
Neuropathol., 32, 59-74 (1997).
- Alexander,
R. W., Transactions of the American Clinical &
Climatological Association, 109, 129-45 (1998);
discussion, 109, 145-6 (1998).
- Fiorillo,
C., Oliviero, C., Rizzuti, G., Nediani, C., Pacini, A.,
and Nassi, P., Clinical Chemistry & Laboratory
Medicine, 36, 149-53 (1998).
- Milam,
S. B., Zardeneta, G., and Schmitz, J. P., Journal of
Oral & Maxillofacial Surgery, 56, 214-23
(1998).
- Tissie,
G., Guillermet, V., Latour, E., Coquelet, C., and Bonne,
C., Ophthalmic Res., 20, 27-30 (1988).
- Varma,
S. D., Devamanoharan, P. S., and Morris, S. M., Critical
Reviews in Food Science & Nutrition, 35,
111-29 (1995).
- Nicolas,
M. G., Fujiki, K., Murayama, K., Suzuki, M. T., Shindo,
N., Hotta, Y., Iwata, F., Fujimura, T., Yoshikawa, Y.,
Cho, F., and Kanai, A., Experimental Eye Research,
62, 399-408 (1996).
- Andersson,
M., Sjostrand, J., Petersen, A., and Karlsson, J. O.,
Ophthalmic Research, 30, 157-67 (1998).
- Miyata,
T., Ishiguro, N., Yasuda, Y., Ito, T., Nangaku, M., Iwata,
H., and Kurokawa, K., Biochem. Biophys. Res. Commun.,
244, 45-9 (1998). 31.
- Calabrese,
V., Raffaele, R., Cosentino, E., and Rizza, V., Intl.
J. Clin. Pharmacol. Res., 14, 119-23 (1994).
- Rando,
T. A., Disatnik, M. H., Yu, Y., and Franco, A., Neuromuscular
Disorders, 8, 14-21 (1998).
- Murphy,
M. E., and Kehrer, J. P., Biochem. J., 260,
359-64 (1989).
- DeWeese,
T. L., Shipman, J. M., Larrier, N. A., Buckley, N. M.,
Kidd, L. R., Groopman, J. D., Cutler, R. G., te Riele,
H., and Nelson, W. G., Proc. Natl. Acad. Sci.,
95, 11915-20 (1998).
-
Meyer, T. E., Liang, H. Q., Buckley, A. R., Buckley, D.
J., Gout, P. W., Green, E. H., and Bode, A. M., International
Journal of Cancer, 77, 55-63 (1998).
-
Stadtman, E. R., and Berlett, B. S., Drug Metabolism
Reviews, 30, 225-43 (1998).
-
Beckman, K. B., and Ames, B. N., Physiol. Reviews,
78, 547-81 (1998).
- >
Nakamura, J., Walker, V. E., Upton, P. B., Chiang, S.
Y., Kow, Y. W., and Swenberg, J. A., Cancer Research,
58, 222-5 (1998).
-
Kubo, K., Ide, H., Wallace, S. S., and Kow, Y. W., Biochemistry,
31, 3703-8 (1992).
-
Ide, H., Akamatsu, K., Kimura, Y., Michiue, K., Makino,
K., Asaeda, A., Takamori, Y., and Kubo, K., Biochemistry,
32, 8276-83 (1993).
-
Asaeda, A., Ide, H., Tano, K., Takamori, Y., and Kubo,
K., Nucleosides & Nucleotides, 17, 503-13
(1998).

DNA Damage Quantification Kit -AP Site Counting-
ARP (Aldehyde Reactive Probe)
Related
Products
Biotin
Labeling Reagents
Amine labeling
Biotin-OSu, Biotin-AC5-OSu, Biotin-(AC5)2-OSu
Biotin-sulfo-OSu, Biotin-AC5-sulfo-OSu
Biotin-(AC5)2-sulfo-OSu
Thiol
labeling
Biotin-PE-maleimide, Biotin-PEAC5-maleimide
Aldehyde
labeling
Biotin-hydrazide, Biotin-AC5-hydrazide
Biotin-(AC5)2-hydrazide
Appearance:
white or slightly yellow powder
Purity: amine, aldehyde reactive biotin >95% (HPLC)
thiol reactive biotin: >90 % (HPLC)
Topics
on Chemistry
Why is the water-soluble formazan necessary?
Table
of Contents
Introduction
Application for clinical test
Application for cytotoxicity assays
Cell
proliferation assay
Cytotoxicity
assay
Conclusion
Reference
Product Information
Munetaka
Ishiyama, Ph.D.
Dojindo Molecular Technologies, Inc.
211 Perry Parkway, Suite 5
Gaithersburg, MD 20877
E-mail: ishi@dojindo.com
Introduction
Tetrazolium
salts are readily reduced enzymatically and generate formazan
dyes. These tetrazolium salts are utilized for the determination
or detection of dehydrogenase activity in tissues or body
fluids for research purposes and for clinical tests. In order
to obtain a clear staining result, highly lipophilic tetrazolium
salts has been required, so most tetrazolium salts are barely
water-soluble, and the resulting formazan dys are insoluble
in water. For the determination of dehydrogenase activities
in the clinical tests, these tetrazolium salts are very useful
reagents. However, the low water-solubility of formazan dyes
causes some troubles upon using these reagents, such as the
precipitation of the dye in the detection solution, the difficulty
for the preparation of the solution of the tetrazolium salt,
the unwanted staining of the detection cells or tubes in autoanalyzers,
and so on. Therefore, we have been developed water-soluble
type tetrazolium salts over a decade. In this topics, I will
introduce how water-soluble tetrazolium salts are being used
an what modification or improvement will be required.
Figure
1. Structure of tetrazolium salt and electron transfer
mechanism
|
Application
for clinical test
Biochemical
tests for measuring clinical important elements in body fluids
are mostly done by enzymatic reactions because of their high
selectivity. These enzymatic reactions are based on oxidase
or dehydrogenase reactions, and these reactions are determined
by colorimetrically or fluorimetrically by using several reagents,
such as oxidative chromogenic dyes or reductive chromogenic
dyes. Tetrazolium salts are one of the reductive chromogenic
dyes, and they provide us the most sensitive detection system.
The reaction cascade is shown in Fig.1.
Generally, a tetrazolium salt is reduced through the reaction
with a reduced form mediator or through the reaction directly
with NADH (nicotineamido adenine dinucleotide reduced form)
or NADPH (nicotineamido adenine dinucleotide phosphate reduced
form), and NADH or NADPH are generated from NAD or NADP by
the reaction of dehydrogenase and its substrate, such as lactate
dehydrogenase and lactic acid. Therefore, the tetrazolium
salt is utilized for the determination of the dehydrogenase
activity or a substrate of the dehydrogenase. The solution
of a tetrazolium salt is almost colorless and its formazan
gives a strongly colored solution, like orange, red or purple.
However, such formazan dyes easily aggregate and precipitate
in the solution after or even during the reaction. In the
clinical tests in Japan, mostly an auto-analyzer is used in
the clinical test center in hospital, and the system for the
detection of clinically important element should be matched
to the system of the auto-analyzer. The formazan dye stains
the auto-analyzer's detection cell and tubes, and gives a
positive error at the detection of the next sample. Therefore,
the improvement of the water-solubility of the formazan dye
became one of the most interesting targets for diagnostic
reagent companies.
WST-1
is a first developed compound that has high water-solubility
and resulting formazan dye is also highly water-soluble. So
far, five different types of WST compounds have been developed
(Figure 2). The water-solubility of these
WST compounds is from 10 mM to 100 mM, and no staining on
plastic surface was observed. Their formazan dye's spectral
properties are shown in Table 1. Since
the molar extinction coefficent of
INT formazan is 15,000 and Nitro-TB formazan is 36,000, these
data shows that the WST compounds have similar molar absorptivity.
However, it should be noted that its molar absorptivity does
not always become an indicator of its sensitivity in the enzymatic
reaction, the affinity between the tetrazolium and the mediator
becomes the most important factor, especially in case of using
diaphorase as a mediator. The maximum wavelengths of WST-4
and WST-5 formazans are around 550 nm at pH 6 or over. However,
the maximum wavelengths of WST-1, 3 and 8 formazans shift
from 440 nm to 600 nm by changing pH from 6 to 12.5, and these
molar absorptivities increase 50 to 100 % more.
Figure
2. Structure of WST compounds
|

Application
for cytotoxicity assays
The
cytotoxicity of chemicals has been determined by animal experiments,
requiring nearly 8 million animals per year in Japan. However,
these assays are not only hard on animals, but also sometimes
unreliable because of the ambiguous standard for the estimation
of the cytotoxicity. Therefore, several alternative methods
for first screening to estimate cytotoxicity have been developed.
The 3H-thymidine incorporate assay and the MTT
(3-(4, 5-dimethyl-2-thiazolyl)-2, 5-dihphenyl-2H-tetrazolium,
bromide) assay are the most common methods among these cytotoxicity
assays. The 3H-thymidine incorporate assay is based
on a measurement of the amount of the tritium labeled thymidine
that is taken in a DNA when DNA is synthesized. On the other
hand, the MTT assay is based on a measurement of the amount
of the yielded formazan dye that was reduced by dehydrogenases
in living cells. The following is introduced concerning cell
proliferation and the cytotoxicity assays using tetrazolium
salts.
1.
Cell proliferation assay
The
cell proliferation assay using tetrazolium salts such as MTT
is a popular method because of its simplicity (colorimetric
assay) and safety (no radioisotope uses such as 3H-thymidine
uptake assay). But there is only one problem in the MTT assay.
The yielded formazan is not soluble in a buffer or a culture
medium. So it is necessary to take an extra step, which is
the solubilization of the formazan using some organic solvents
before the measurement of the optical density. Dojindo Laboratories
has developed and started to sell a new type of cell proliferation
assay kit for a 96-well microtiter plate, "Cell Counting
Kit-8 (CCK-8)," which employs WST-8 which produces a
highly water-soluble formazan dye. Since CCK-8 is supplied
as a one-bottled ready-to-use solution, no dilution with a
buffer or a culture medium nor mixing with solutions is necessary
prior to use. Furthermore, CCK-8 does not require any radioisotopes
nor organic solvents, and no special skills are necessary
for use. CCK-8 consists of WST-8 (5 mM) and 1-methoxy PMS
(0.2 mM) as an electron mediator, and the kit solution is
stable for over 1 year at -20 ºC and over 3 months at
4 ºC with protection from light. The cell proliferation
assay procedure is very simple. Ten
of the kit solution is added to each well of the plate on
which is inoculated 100
of the cell suspension. After the plate is incubated for 1-4
hours in the incubator, the absorbance is measured using a
microplate reader. The wavelength range for the measurement
of the absorbance is between 450 nm and 490 nm. So the researcher
is able to choose a popular filter, for example 450 nm or
490 nm. The amount of the yellow colored formazan dye generated
by dehydrogenases in cells is directly proportional to the
number of viable cells in a culture medium. The sensitivity
using CCK-8 is higher than that using MTT or the other tetrazolium
salts that produce water-soluble formazan dyes such as XTT
or MTS for HeLa cells and HL60 cells. Furthermore, the cell
proliferation assay data using CCK-8 correlates with that
using the 3H-thymidine incorporate assay.

Figure
3. Cell proliferation assay using CCK-8 and other reagents
|
2.
Cytotoxicity assay
The
cytotoxicity assays of the several detergents and chemicals
for Hela, Balb3T3, L929, RC and HL60 cells were tested by
use of CCK-8. A ten
of various concentration detergents or chemicals is added
to 100
of the cell suspensions (5000 cells/well) that are dispensed
onto each well of a 96-well microtiter plate. After the plate
is incubated for 48 hours in the incubator, 10
of CCK-8 solution is added. The plate is incubated for an
additional 1-4 hours, and then the absorbance is measured
using the microplate reader. The IC50 values (chemicals
concentrations in a 50 % inhibition of growth) of detergents
and chemicals are shown in Table 2. The IC50 values
using CCK-8 correlate with those using MTT.
|

|
|
Figure 4. Toxicological test of chemicals by using CCK-8
|
Table
2. Comparision of LD50 values using CCK-8 and MTT
| cell
line |
antitumor
agent |
LD50/
CCK8 (ug/ml) |
LD50/
MTT (ug/ml) |
| HE49
|
bleomycin
cisplatin
adriamycin
MMC
etoposide
5-FU
|
154.59
1.55
0.41
0.05
13.01
0.12
|
157.34
1.61
0.47
0.03
13.18
0.37 |
| MKN-28
|
bleomycin
cisplatin
adriamycin
MMC
etoposide
5-FU |
151.18
0.57
0.11
0.02
4.11
0.05 |
139.51
0.60
0.13
0.02
4.63
0.05 |
| IMR-32
|
bleomycin
cisplatin
adriamycin
MMC
etoposide
5-FU |
314.15
5.65
2.27
0.10
9.63
0.04 |
207.00
5.32
0.33
0.10
9.71
0.05 |
| H1299
|
bleomycin
cisplatin
adriamycin
MMC
etoposide
5-FU |
406.65
0.51
0.17
0.04
14.63
0.08 |
1057.12
0.72
0.14
0.06
25.96
0.05 |
| HL60
|
bleomycin
cisplatin
adriamycin
MMC
etoposide
5-FU |
280.74
1.54
0.19
0.02
12.23
0.06 |
190.84
1.00
0.24
0.03
11.32
0.07 |
| MOLT-4
|
bleomycin
cisplatin
adriamycin
MMC
etoposide
5-FU |
218.84
0.94
0.27
0.01
3.87
0.11 |
187.26
1.04
0.24
0.01
4.27
0.11 |
| KC12
|
bleomycin
cisplatin
adriamycin
MMC
etoposide
5-FU |
739.05
3.59
0.37
0.15
52.87
0.20 |
880.56
2.98
0.48
0.11
53.31
0.19 |
| HeLa
|
bleomycin
cisplatin
adriamycin
MMC
etoposide
5-FU |
306.89
15.22
1.56
0.18
79.16
0.71 |
379.24
11.52
1.98
0.14
58.37
0.78 |
| Cell
lines (human) |
MKN-28:
gastric cancer |
| HE
49: normal embryo |
|
| IMR-32:
neuroblastoma |
H1299:
lung cancer |
| HL60:
acute promyelonic leukemia |
KC12:
renal cancer |
| MOLT-4:
acute lympphoblastic leukemia |
Hela:
cervical cancer |
Conclusion
Because of high water-solubility of formazan dyes derived
from WSTs, it was found that they are preferable reagents
for clinical analyses and cell proliferation. In clinical
analyses, the sensitivity of the detection of analytes such
as a dehydrogenase and its substrate using WSTs is equal or
greater than conventional tetrazolium salts such as INT, MTT
or NBT. In addition, WSTs are able to apply the cytotoxicity
assay as a reductive chromogenic dye that can minimize the
process of the determination of living cell number. Therefore,
the cytotoxicity assay using WSTs is suitable for the first
screening of the determination of cytotoxicity of chemicals,
and contributes to reduce the consumption of experimental
animals.Dojindo has been focused on the improvement of the
water-solubility of tetrazolium salts over a decade, and we
believe that the WSTs are the best reagents for the determination
of dehydrogenase activity and the concentration of its substrate
among water-soluble type tetrazolium salts. One of our goals
of this project is to develop a WST that generates a blue
or green color formazan or a fluorescent formazan in an aqueous
solution.
References
- Rodriguez,
R. M., Toledano, A., and Gonzalez, M., Ann.
Histochem., 17, 215 (1972).
- Kugler,
P., Histochemistry, 75, 99
(1982).
- Butcher,
R. G., Histochemistry, 81, 567 (1984).
- Segal,
A. W., and Levi, A. J., Clin. Sci. Mol. Med.,
45, 817 (1973).
- Anderson,
G. L., and Deinard, A. S., J. Med. Technol., 40,
345 (1974).
- MacDonald,
D., Pang, C. P., Cockram, C. S., and Swaminathan, R.,
Clin. Chim. Acta., 168, 247 (1987).
- Kallner,
A., Clin. Chim. Acta, 207, 99 (1992).
- Campbell,
R. S., Brearley, G. M., Vasani, H., Morris, H. C., Milligan,
T. P., Hall, S. K., Hammond, P. M., and Price, C. P.,
Clin. Chim. Acta, 210, 197 (1992).
- Beauchamp,
C., and Fridovich, I., Anal. Biochem., 44,
276 (1971).
- Podczasy,
J. J., and Wei, R., Biochem. Biophys. Res. Comm., 150,
1294 (1988).
- Durak,
I., Yurtarslanl, Z., and Akyol, O., Clin. Chim. Acta,
214, 103 (1993).
- Cross,
A. R., Yarchover, J. L., and Curnutte, J. T., J. Biol.
Chem., 269, 1448 (1994).
- Ishiyama,
M., Shiga, M., sasamoto, K., Mizoguchi, M., and He, P.
–G., Chem. Pharm. Bull., 41, 1118
(1993).
- Ishiyama,
M., Sasamoto, K., Shiga, M., Ohkura, Y., and Ueno, K.,
Analyst, 120, 113 (1995).
- Ishiyama,
M., Miyasono, Y., Shiga, M., Sasamoto, K., Ohkura, Y.,
and Ueno, K., Anal. Sci., 12, 515 (1996).
- Ishiyama,
M., Tominaga, H., Shiga, M., Sasamoto, K., Ohkura, Y.,
Ueno, K., and Watanabe, M., In Vitro Toxicol.,
8, 187 (1995).
- Mosmann,
T., J. Immunol. Methods, 65, 55 (1983).
- Borenfreund,
E., and Puerner, J. A., J. Tissue Cul. Meth.,
9, 7 (1984).
- Borenfreund,
E., and Puerner, J. A., Toxicol. Lett., 24,
119 (1985).
- Saotome,
K., Morita, H., and Umeda, M., Toxicol. In Vitro, 3,
317 (1989).
- Itagaki,
H., Hagino, S., Kobayashi, T., and Umeda, M., Toxicol.
In Vitro, 5, 139 (1991).
- Yano,
T., Teruya, K., Shirahata, S., Watanabe, J., Osada, K.,
Tachibana, H., Ohashi, H., Kim, E. H., and Murakami, H.,
Cytotechnology, 16, 167 (1994).
- Teruya,
K, Yano, T., Shirahata, S., Watanabe, J., Osada, K., Ohashi,
H., Tachibana, H, Kim, E. H., and Murakami, H., Biosci.
Biotech. Biochem., 59, 341 (1995).
- Iwai,
T., Iwaki, A., Fukumaki, Y., and Tateishi, J., Brain
Res., 673, 47 (1995).
- Liu,
S. Q., Saijo, K., Todoroki, T., and Ohno, T., Nature
Med., 1, 267 (1995).
- Takenouchi,
T., and Munekata, E., Life Sci., 56, 479
(1995).

1
bottle type (WST-8, 1-Methoxy PMS)
Colorimetric microplate assay
Storage -20 C
Cell Counting Kit-F (CCK-F)
| Product
Code |
Unit
|
| CK06-10
|
500
tests |
DMSO solution
(Calcein-AM)*
Fluorometric microplate assay
Storage: -20 oC
*Reagent dilution buffer is required
WST-1
| Product
Code |
Unit
|
| W201
|
100
mg |
| W201
|
500
mg |
MW:
651.35
Appearance: slightly yellow powder
Purity: pass test (TLC)
Molar absorptivity (tetrazolium): >21,600 (244 nm)
Molar absorptivity (formazan): >37,000 (438 nm)
Solubility: 10 mg/ml water
Storage: 0-5 oC
WST-3
| Product
Code |
Unit
|
| W202
|
100
mg |
| W202
|
500
mg |
MW:
696.34
Appearance: slightly yellow powder
Purity: pass test (TLC)
Molar absorptivity (tetrazolium): >36,000 (234 nm)
Molar absorptivity (formazan): >30,000 (433 nm)
Solubility: 10 mg/ml water
Storage: 0-5 oC
WST-4
| Product
Code |
Unit
|
| W203
|
100
mg |
| W203
|
500
mg |
MW:
580.59
Appearance: slightly yellow powder
Purity: pass test (TLC)
Molar absorptivity (tetrazolium): >28,000 (264 nm)
Molar absorptivity (formazan): >10,000 (550 nm)
Storage: 0-5 oC
WST-5
| Product
Code |
Unit
|
| W204
|
100
mg |
| W204
|
500
mg |
MW:
1331.35
Appearance: slightly yellow powder
Purity: pass test (TLC)
Molar absorptivity (tetrazolium): >50,000 (264 nm)
Molar absorptivity (formazan): >27,000 (550 nm)
Storage: 0-5 oC
Electron
Mediator
MW:
336.36
Appearance: dark red or reddish purple powder
Purity: >95%
m.p.: >170 oC (dec.)
Molar absorptivity: >2,700 (505 nm)
Solubility: 34 mg/100 ml water
|
 |
 |
|